Optikusneuritis

Zusammenfassung

Die Optikusneuritis ist eine häufige neuroophthalmologische Erkrankung, deren Diagnose meistens auf wenige Symptome und Befunde gestützt werden kann. Wichtig ist nicht nur die Abgrenzung zu anderen Sehnervenerkrankungen, sondern auch die Diagnose von Sonderformen, was häufig erst im Verlauf möglich ist. Diese Übersichtsarbeit will den aktuellen Stand hinsichtlich Diagnostik und Therapie aus der Sicht der Autoren wiedergeben.

Abstract

Optic neuritis is a frequent neuro-ophthalmological disease in which the diagnosis can be based on just a few symptoms and findings. It is not only important to differentiate from other optic nerve disorders but also to recognise special types of optic neuritis, which is mostly only possible during the course of the disease. This article presents a review of the current state in diagnosis and therapy from the authorsʼ personal point of view.

Schlüsselwörter

Neuroophthalmologie - Optikusneuropathie - multiple Sklerose - Neuromyelitis optica - Neuroretinitis

Key words

neuro-ophthalmology - optic neuropathy - multiple sclerosis - neuromyelitis optica - neuroretinitis

• Literatur

• 1 Beisse F, Beisse C, Lagreze WA et al. Aktuelle Empfehlungen zu Neuritis nervi optici. Ophthalmologe 2014; 111: 722-726
• 2 Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler 2014; 20: 520-526
• 3 Miller DH, Fazekas F, Montalban X et al. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 2014; 20: 527-536
• 4 DGN/KKNMS Leitlinie zur Diagnose und Therapie der Multiplen Sklerose. 2012 Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/030-050l_S2e_Multiple_Sklerose_Diagnostik_Therapie_2014-06.pdf Stand: 14.08.2014
• 5 Trobe JD. The Neurology of Vision. Oxford: Oxford University Press; 2001
• 6 Davis FA, Bergen D, Schauf C et al. Movement phosphenes in optic neuritis: a new clinical sign. Neurology 1976; 26: 1100-1104
• 7 Fraser CL, Davagnanam I, Radon M et al. The time course and phenotype of Uhthoff phenomenon following optic neuritis. Mult Scler 2011; 18: 1042-1044
• 8 Nevalainen J, Krapp E, Paetzold J et al. Visual field defects in acute optic neuritis–distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol 2008; 246: 599-607
• 9 Keltner JL, Johnson CA, Spurr JO et al. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993; 111: 231-234
• 10 Ong HS, Fraser C, Davagnanam I et al. Acute visual loss in papilloedema: the diagnostic pitfalls. Int Ophthalmol 2014; 34: 607-612
• 11 Braun F, Wilhelm H. Farbvergleichstests bei einseitigen Optikusneuropathien. Klin Monatsbl Augenheilkd 2010; 227: 852-856
• 12 Fernandes DB, Ramos Rde I, Falcochio C et al. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 2012; 32: 102-106
• 13 Beck RW, Cleary PA, Anderson jr. MM et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588
• 14 Traisk F, Lindquist L. Optic nerve involvement in Lyme disease. Curr Opin Ophthalmol 2012; 23: 485-490
• 15 Trauzettel-Klosinski S, Diener HC, Fahle M. Vergleich des Flimmertests nach Aulhorn mit den visuell evozierten Potentialen in der Diagnostik der Neuritis nervi optici. Fortschr Ophthalmol 1990; 87: 171-177
• 16 Batra M. Magnetresonanztomografie in der neuroophthalmologischen Diagnostik. Klin Monatsbl Augenheilkd 2011; 228: 957-962
• 17 Polman CH, Wolinsky JS, Reingold SC. Multiple sclerosis: should MR criteria for dissemination in time be less stringent. Ann Neurol 2004; 55: 297
• 18 Group ONS. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727-732
• 19 Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840-846
• 20 Polman CH, Koetsier JC, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clin Neurol Neurosurg 1985; 87: 187-192
• 21 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
• 22 Kieseier BC, Wiendl H. Transforming multiple sclerosis trials into practical reality. Lancet Neurol 2011; 10: 493-494
• 23 Mealy MA, Wingerchuk DM, Greenberg BM et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69: 1176-1180
• 24 Marques IB, Matias F, Silva ED et al. Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 2013; 21: 583-586
• 25 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
• 26 Oberwahrenbrock T, Schippling S, Ringelstein M et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012; 2012: 530305
• 27 Balk LJ, Killestein J, Polman CH et al. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain 2012; 135: e226
• 28 Gelfand JM, Nolan R, Schwartz DM et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012; 135: 1786-1793
• 29 Petzold A. Microcystic macular oedema in MS: T2 lesion or black hole?. Lancet Neurol 2012; 11: 933-934
• 30 Saidha S, Sotirchos ES, Ibrahim MA et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11: 963-972
• 31 Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
• 32 Thoo S, Cugati S, Lee A et al. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Mult Scler Epub April 2, 2014
• 33 Trobe JD, Beck RW, Moke PS et al. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol 1996; 121: 547-553
• 34 van Rijn LJ, Wilhelm H, Emesz M et al. Relation between perceived driving disability and scores of vision screening tests. Br J Ophthalmol 2002; 86: 1262-1264
• 35 Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 2008; 126: 994-995
• 36 Morrow MJ, Wingerchuk D. Neuromyelitis optica. J Neuroophthalmol 2012; 32: 154-166
• 37 Jarius S, Frederikson J, Waters P et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158-162
• 38 Merle H, Olindo S, Jeannin S et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012; 130: 858-862
• 39 Kleiter I, Hellwig K, Berthele A et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239-245
• 40 Wender M. Acute disseminated encephalomyelitis (ADEM). J Neuroimmunol 2011; 231: 92-99
• 41 Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol 2011; 31: 58-68
• 42 Sundaram SV, Purvin VA, Kawasaki A. Recurrent idiopathic neuroretinitis: natural history and effect of treatment. Clin Experiment Ophthalmol 2010; 38: 591-596
• 43 Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2013; 261: 17-26
• 44 Beck RW. The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol 1992; 110: 331-332
• 45 Schmidt J, Gold R, Schonrock L et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431-1441
• 46 Garcia-Segura LM, Balthazart J. Steroids and neuroprotection: New advances. Front Neuroendocrinol 2009; 30: v-ix
• 47 Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001; 117: 1-8
• 48 Trobe JD, Sieving PC, Guire KE. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999; 106: 2047-2053
• 49 Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247
• 50 Zivadinov R, Zorzon M, De Masi R et al. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci 2008; 267: 28-35
• 51 Diem R, Hobom M, Maier K et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993-7000
• 52 Dimitriu C, Bach M, Lagreze WA et al. Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest Ophthalmol Vis Sci 2008; 49: 5003-5007
• 53 Sellebjerg F, Nielsen HS, Frederiksen JL et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479-1484
• 54 Burton JM, OʼConnor PW, Hohol M et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009; CD006921
• 55 Schilling S, Linker RA, König FB et al. Plasmaaustausch bei steroidresistenten Multiple-Sklerose-Schüben: Klinische Erfahrungen an 16 Patienten. Nervenarzt 2006; 77: 430-438
• 56 Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121: 944-949
• 57 Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904
• 58 Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol 2001; 21: 292-295
• 59 Kinkel RP, Dontchev M, Kollman C et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012; 69: 183-190
• 60 Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249
• 61 Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582
• 62 Comi G, Martinelli V, Rodegher M et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511
• 63 Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008; 71 (Suppl. 03) S3-S7
• 64 OʼConnor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
• 65 OʼConnor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303
• 66 Gold R, Kappos L, Arnold DL et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107
• 67 Sühs K-W, Hein K, Sättler MB et al. A randomized, double-blind, phase II study on erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199-210
• 68 Tsakiri A, Kallenbach K, Fuglo D et al. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72-81
• 69 Rudick RA, Mi S, Sandrock jr. AW. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008; 8: 1561-1570